• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral appliance for Obstructive Sleep Apnea: Prototyping and Optimization of the Mandibular Protrusion Device
AbstractObstructive Sleep apnea is a public health problem. This disease is associated with daytime sleepiness, increased motor vehicle accidents, heart failure and stroke. Treatment options include weight loss, positive airway pressure, pharyngeal and orthognatic surgery. However, selected patients have good response to oral appliances devices that intended to protrude and stabilize the mandible mechanically during the night in order to reduce the collapsibility of the upper airway. Selection of patients includes primary snoring, mild, moderate and positional apnea. The perfect mandibular advance device has not yet been d...
Source: Journal of Medical Systems - March 17, 2019 Category: Information Technology Source Type: research

Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Authors: Madsbad S Abstract INTRODUCTION: The GLP-1 receptor agonist (GLP-1 RA) liraglutide has a half-life of approximately 13 h and is suitable for subcutaneous administration once daily. The use of liraglutide in people with type 2 diabetes has become popular because of the efficacy and durability in relation to glycemic control in combination with weight loss in most patients. Areas covered: PubMed searches were completed using the terms "GLP-1 receptor agonist", "Liraglutide", "Liraglutide and CVD", "Liraglutide and CVD risk factors". The reference list of articles subsequently identified was searched and arti...
Source: Expert Review of Cardiovascular Therapy - May 7, 2019 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients.
Conclusion: SGLT2 inhibitors are novel antidiabetic medications with immense utility in the management of patients with T2DM. Furthermore, SGLT2 inhibitors have demonstrated to reduce the progression to advanced forms of kidney disease and its associated complications. These medications should be front and center in the management of patients with diabetic kidney disease with and without chronic kidney disease as they confer protection against cardiovascular/renal death and improve all-cause mortality. Future studies should evaluate the benefits and implications of early initiation of SGLT2 inhibitors, as well as the long-...
Source: International Journal of Nephrology and Renovascular Disease - November 7, 2020 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Effect of Bariatric Surgery on Cardiovascular Function and Heart Failure Outcomes
In this article, we explore the influence of obesity on cardiovascular health and the role of bariatric surgery in reducing cardiovascular comorbidities, preventing the onset of heart failure and improving mortality and quality of life in those with cardiac dysfunction. We highlight the mechanisms by which obesity leads to cardiovascular remodeling, diastolic dysfunction, and eventual heart failure. These mechanisms include systemic inflammation, local lipotoxicity by way of ectopic fat deposition, and hemodynamic alterations that have significant effects on cardiac structure and function. Bariatric surgery has been shown ...
Source: Cardiology in Review - June 11, 2021 Category: Cardiology Tags: Review Articles Source Type: research

Prevention of Diabetes Macrovascular Complications and Heart Failure
Cardiovascular (CV) mortality in diabetes has declined substantially over the last 3  decades in high-income countries from a multifactorial approach targeting glucose, cholesterol, and blood pressure, and lower smoking rates. Additional CV gains may be achieved from large-scale weight loss, which ongoing trials are testing, and from delaying diabetes in those at highest risk. Fina lly, recent outcome trials support a role for (1) sodium/glucose cotransporter-2 inhibitors, which lower major adverse cardiovascular events but incident heart failure more strongly, and (2) glucagon-like peptide-1 receptor agonists, which lowe...
Source: Endocrinology and Metabolism Clinics of North America - July 12, 2021 Category: Endocrinology Authors: Naveed Sattar Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation
Physiol Res. 2021 Dec 30;70(Suppl4):S511-S525.ABSTRACTAtrial fibrillation (AF) is the most common sustained cardiac arrhythmia associated with a two-fold increase in mortality caused by a higher risk of stroke and heart failure. Currently, AF is present in ~ 2 % of the general population, and its incidence and prevalence are increasing. Obesity, hypertension, diabetes mellitus, obstructive sleep apnea, and alcohol consumption increase the risk of AF. Each unit of increase in BMI increases the risk of AF by 3 %, and intensive weight loss is also associated with reduced AF recurrence. Hypertension increases the risk of AF by...
Source: Physiological Research - February 24, 2022 Category: Physiology Authors: Z Čarná P Osman čík Source Type: research

Obesity paradox and cardiovascular diseases
Curr Cardiol Rev. 2022 May 14. doi: 10.2174/1573403X18666220514150051. Online ahead of print.ABSTRACTThe present review summaries data describing the relationship between obesity and cardiovascular outcomes. Links between obesity and chronic coronary syndromes, acute coronary syndromes, coronary revascularization, ischemic stroke, heart failure, hypertension and atrial fibrillation were evaluated. Data from epidemiological studies, prospective studies with lifestyle modification or medical therapy, and results of the meta-analysis were evaluated. The majority of publications report the presence of an 'obesity paradox'. Acc...
Source: Current Cardiology Reviews - May 16, 2022 Category: Cardiology Authors: Isayeva Ganna Shalimova Anna Source Type: research

Disturbed Sleep is Not Good for the Heart: A Narrative Review
Curr Cardiol Rev. 2022 Nov 30. doi: 10.2174/1573403X19666221130100141. Online ahead of print.ABSTRACTSleep-related breathing disorders, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), have a major impact on cardiovascular function. It has shown an association with hypertension, coronary artery disease, cardiac arrhythmias, sudden cardiac death, and congestive heart failure (CHF). This review focuses on highlighting the relationship between sleep apnea and CHF. We discuss the underlying pathophysiology which involves the mechanical, neurohormonal, and inflammatory mechanisms; in addition, the similari...
Source: Current Cardiology Reviews - December 1, 2022 Category: Cardiology Authors: Meet Patel Harshani Yarlagadda Shubekshya Upadhyay Ritesh Neupane Umer Qureshi Joseph D Raco Rahul Jain Rohit Jain Source Type: research

Prevention of Cardiovascular Events in Patients With Chronic Kidney Disease
CONCLUSIONS: Patients diagnosed with chronic kidney disease have markedly increased risk of cardiovascular events, including myocardial infarction, stroke, heart failure, and cardiovascular death. However, until recently, there were few cardiovascular outcome studies that targeted enrollment specifically to those patients. Certain drugs now have shown benefits to cardiovascular end points in this population.PMID:37029538 | DOI:10.1177/10600280231165774
Source: The Annals of Pharmacotherapy - April 8, 2023 Category: Drugs & Pharmacology Authors: Chris M Terpening Source Type: research

Pages: 1  2  3  4  5  6  7